World First Early Stage Diagnostic Test for Ovarian Cancer

Press release from Australian Company HealthLinx Limited

There is now new hope for women around the world, with the launch of an early detection test for ovarian cancer, according to HealthLinx Limited. The test, developed in Melbourne by HealthLinx scientists in collaboration with ARL Pathology, is called the OvPlex™ Panel and works by identifying whether five biomarkers (proteins) are present in a blood sample.

OvPlex™ is a new type of blood test. The difference between current blood tests and OvPlex™ is that OvPlex™ measures five different substances in blood that are associated with ovarian cancer and builds a diagnostic based on that information rather than relying on a single marker for the disease. Chairman of HealthLinx Limited, Professor Greg Rice, who helped develop the technology, said: “This is really what I see as a new generation of diagnostics.”

CEO of ARL Pathology, Pam Davey, said: "Women all around the world will benefit. Until now no test has been available. By putting the five biomarkers together, we really increase the chances of detecting ovarian cancer early.”

HealthLinx scientists stress this is not a general community screening test, rather a diagnostic test. The test will be available through general practitioners in Melbourne from 29th October, before being rolled out to other states across Australia. It will cost around $200. Results are available within a fortnight.

 

19.11.2008

Related articles

Photo

News • Noninvasive fetal screening

Blood test to identify genetic diseases in unborn babies

A research team from Denmark has developed an innovative screening test. With a blood sample from the expectant mother, they can scrutinize all the genes in the fetus.

Photo

News • Maternal serum and ultrasound assessment

New method to predict outcomes of pregnancies with foetal growth problems

New methods to predict outcomes for pregnancies where there are issues with poor growth of the baby inside the womb have been developed by a team of scientists.

Photo

News • Early detection & prevention

Blood-based micro-RNAs indicate colorectal cancer risk

The risk of colorectal cancer can be predicted more accurately by determining seven blood-based micro-RNAs (miRNAs) than by using traditional methods - and can be done so many years before a…

Related products

Subscribe to Newsletter